Dear Colleague,
Kinases, key drivers of malignant transformation and major
contributors to a variety of other human pathologies, have emerged
as some of the most exciting targets in drug discovery. However,
with initial well documented success stories came realization that
many hurdles lie in the path of successful development of new drugs,
targeting kinase signaling. GTC’s Protein Kinases
and Drug Design conference will bring together speakers representing world leading academic
centers and pharmaceutical companies to discuss how to overcome the
many hurdles and answer exciting key questions such as:
- What are the best approaches to identify key kinases contributing
to neurodegenerative diseases and major forms of human cancer from
leukemias and breast cancer to malignant gliomas?
- How do different factors, including genetic background,
interactions with stroma, “stemness” of the tumor cells contribute
to tumor responses to kinase inhibitors?
- What are the best computational, chemical biology and structural
biology approaches to de novo kinase drug design, including a “holy
grail” of kinase drug discovery - non-ATP competitive inhibitors?
- What is the right balance between inhibitor selectivity and
activity?
- Are covalent inhibitors a “no-no” in drug discovery?
- What have we learned from the use of the latest generation of
inhibitors, targeting many of the hottest pathways (PI3K, Her2, CDKs,
JNK) in pre-clinical models and clinical trials?
- How can we predict pharmacological properties of new kinase
inhibitors?
Experts will also share their positive and negative experiences on
how predictive preclinical models are with clinical efficacy and
toxicology. This conference is one of two parallel tracks of
the Cancer Summit - Novel Approaches to Drug Discovery
on November 8-9 in Boston, MA.
Sessions of the Protein Kinases and Drug Design conference:
Recent Advances in Drug Design & Development
Selective vs Non-selective Kinases Inhibitors
Recent Advancements in Hit and Target Identification
Novel Oncology Kinases & Inhibitors
Preclinical Models – How Predictive
Are They?
Kinase Targets in Pre-clinical and Clinical Trials
To view the agenda,
click
here.
To view the speaker list,
click here.
The conference will run parallel with the
2nd Cancer Epigenetics conference,
which brings together a balanced mix of leading experts from the industry and
academia to collaborate on the latest cutting edge research on novel mechanisms,
therapeutics, drug discovery, developments, biomarkers and diagnostics for
cancer epigenetics.
Sign up for the summit
pass to have access to both tracks of the summit. Or bring a team of 3 for the
price of 2 by
Registering
with the coupon code rcdvb!
We look forward to seeing you at the
conference!
Sincerely,
2012 Protein Kinases Inhibitors and Drug Design Conference Organizing Committee |
What Past Delegates said:
“Fantastic opportunity to see the very latest research in
epigenetics drug-discovery.” - Rab Prinjha, VP Head of
Epinova DPU, GSK
"The conference was a huge success, bringing together the
top-leaders and innovators in the protein kinase field,
where new screening technologies and the most late-breaking
clinical kinase targeting drugs were disclosed. The group is
growing in numbers each year, but still remains quite
manageable to allow for one-on-one interactions and
networking. This conference has become indispensable for
those in the kinase drug discovery field." - Mark Mulvihill,
Associate Director of Chemistry, Oncology, OSI
Pharmaceuticals
"The meeting provides an excellent snapshot of the
up-to-date state of kinase drug discovery with inputs from
both academia and industry. It covers all aspects of the
field starting from discussion of well established as well
as new emerging kinase targets to the novel classes of small
molecule inhibitors to new exciting technologies to study
kinases. It also provides ample opportunities for networking
and establishing new collaborations." - Dr. Alexei Degterev,
Assistant Professor, Tufts University
“An excellent meeting with good organization and top quality
speakers and attendees from academia and bio-pharmaceutical
as well and biotechnology industry.” - Pfizer
|
|
